We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

42 hedge funds and large institutions have $83.6M invested in Xenon Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

169% more capital invested

Capital invested by funds: $31.1M → $83.6M (+$52.5M)

117% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 6

29.09% more ownership

Funds ownership: 35.28% → 64.37% (+29%)

20% more funds holding

Funds holding: 35 → 42 (+7)

13% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 8

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
42
Holders Change
+7
Holders Change %
+20%
% of All Funds
0.96%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
13
Increased
9
Reduced
8
Closed
6
Calls
$4K
Puts
–
Net Calls
+$4K
Net Calls Change
+$4K

Top Buyers

1
ACA
Avoro Capital Advisors
New York
+$7.47M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$4.97M
3
GPCM
Granite Point Capital Management
Massachusetts
+$3M
4
ACP
Acuta Capital Partners
California
+$2.8M
5
SFM
Sphera Funds Management
Israel
+$2.73M

Top Sellers

1
NC
Nexthera Capital
New York
-$1.86M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.42M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.21M
4
TCM
Tekla Capital Management
Massachusetts
-$722K
5
IPC
Invesco Private Capital
New York
-$578K
Name Holding Trade Value Shares
Change 		Change in
Stake
Capital World Investors
1
Capital World Investors
California
$13.1M – – –
ACA
2
Avoro Capital Advisors
New York
$11.1M +$7.47M +1,202,118 New
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$7.36M +$4.97M +800,000 New
BI
4
BVF Inc
California
$6.63M – – –
O
5
OrbiMed
New York
$5.84M – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$4.5M +$1.25M +201,500 +70%
GPCM
7
Granite Point Capital Management
Massachusetts
$4.44M +$3M +482,200 New
SSA
8
Schonfeld Strategic Advisors
New York
$4.19M +$435K +70,000 +18%
ACP
9
Acuta Capital Partners
California
$4.14M +$2.8M +450,000 New
SFM
10
Sphera Funds Management
Israel
$4.04M +$2.73M +439,034 New
DCM
11
DAFNA Capital Management
California
$2.71M -$518K -83,333 -22%
IPC
12
Invesco Private Capital
New York
$2.29M -$578K -93,061 -27%
DMK
13
David M. Knott
$1.59M +$363K +58,490 +51%
TCM
14
Tekla Capital Management
Massachusetts
$1.51M -$722K -116,181 -41%
State of New Jersey Common Pension Fund D
15
State of New Jersey Common Pension Fund D
New Jersey
$1.43M +$560K +90,100 +139%
AG
16
Artal Group
Luxembourg
$1.38M – – –
Deutsche Bank
17
Deutsche Bank
Germany
$1.11M +$753K +121,223 New
Royal Bank of Canada
18
Royal Bank of Canada
Ontario, Canada
$1.07M – – –
Point72 Asset Management
19
Point72 Asset Management
Connecticut
$719K -$1.42M -228,979 -75%
PVI
20
Pura Vida Investments
New York
$690K +$466K +75,000 New
California Public Employees Retirement System
21
California Public Employees Retirement System
California
$506K – – –
NSEDCP
22
NJ State Employees Deferred Compensation Plan
New Jersey
$460K +$186K +30,000 +150%
JC
23
JBF Capital
Colorado
$368K +$249K +40,000 New
BFM
24
Boothbay Fund Management
New York
$325K +$219K +35,319 New
SC
25
Scotia Capital
Ontario, Canada
$314K – – –
1
2

XENE Hedge Fund Activity: Q2 2018 in Review

42 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2018, worth a combined $83.6M — up 169% from $31.1M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new XENE positions and 6 closed out — a net gain of 7 holders — while 9 added to existing stakes and 8 trimmed.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $7.47M. The largest seller was Nexthera Capital, exiting entirely with an estimated $1.86M sold.

  • 42 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2018, up from 35 in Q1 2018.
  • Funds reported $83.6M of Xenon Pharmaceuticals stock for Q2 2018, up 169% quarter-over-quarter.
  • 13 funds opened new Xenon Pharmaceuticals positions in Q2 2018 and 6 closed out, a net change of +7 holders.
  • The largest Xenon Pharmaceuticals buyer in Q2 2018 was Avoro Capital Advisors, an estimated $7.47M added.
  • The largest Xenon Pharmaceuticals seller in Q2 2018 was Nexthera Capital, an estimated $1.86M sold.

Based on aggregated 13F filings for Q2 2018.